Chai R, Ye Z, Zhan Z, Liu W, Yu M, Liu Y
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730.
Zhonghua Nei Ke Za Zhi. 1999 Jan;38(1):18-21.
To investigate the effects of short-term thyroid hormone replacement therapy on bone and mineral metabolism in patients with hypothyroidism.
Enzyme linked immunosorbent assay (ELISA) was used to measure urinary deoxypyridinoline (DPD) and radioimmunoassay (RIA) to measure serum calcitonin (CT), parathyroid hormone (PTH-M), bone GLA protein (BGP), free T(3) (FT(3)), free T(4) (FT(4)) and thyroid-stimulating hormone (TSH) in 29 patients with hypothyroidism before and after treatment with levothyroxine for (11.5 +/- 2.5) months. Dual energy X-ray absorptiometry was used to measure bone mineral density (BMD) of their spine (L(2 - 4)) and femur neck, trochanter and Ward's triangle. The results were compared with those in 37 healthy controls.
In hypothyroidism patients before treatment, serum BGP level was significantly lower (P < 0.05) than but urinary DPD was similar with those of control. BMD was significantly lower in postmenopausal patients (P < 0.01 - 0.001) than that in control group, but there was no change in premenopausal patients. After replacement therapy serum BGP and urinary DPD elevated significantly (P < 0.05), whereas BMD decreased slightly both in the premenopausal and postmenopausal patients when compared with that before treatment, with no statistical significance (P > 0.05). BMD decreased by 0.7% and 1.7% - 5.1% in premenopausal and postmenopausal patients respectively, but there was no significant difference between these two groups (P > 0.05). FT(3) was positively correlated with BGP. FT(4) and FT(3) were positively correlated with DPD. BMD of femur neck and trochanter sites was negatively correlated with FT(4).
Short-term physiological dose levothyroxine replacement therapy causes increase of bone turnover and leads to bone mass loss to various extent on hypothyroidism patients.
探讨短期甲状腺激素替代治疗对甲状腺功能减退症患者骨与矿物质代谢的影响。
采用酶联免疫吸附测定法(ELISA)检测29例甲状腺功能减退症患者在左甲状腺素治疗(11.5±2.5)个月前后的尿脱氧吡啶啉(DPD),采用放射免疫测定法(RIA)检测血清降钙素(CT)、甲状旁腺激素(PTH-M)、骨钙素(BGP)、游离三碘甲状腺原氨酸(FT₃)、游离甲状腺素(FT₄)及促甲状腺激素(TSH)。采用双能X线吸收法测量其腰椎(L₂₋₄)、股骨颈、大转子及Ward三角区的骨密度(BMD)。将结果与37名健康对照者的结果进行比较。
甲状腺功能减退症患者治疗前血清BGP水平显著低于对照组(P<0.05),但尿DPD与对照组相似。绝经后患者的BMD显著低于对照组(P<0.01-0.001),但绝经前患者无变化。替代治疗后,血清BGP和尿DPD显著升高(P<0.05),而绝经前和绝经后患者的BMD与治疗前相比略有下降,无统计学意义(P>0.05)。绝经前和绝经后患者的BMD分别下降了0.7%和1.7%-5.1%,但两组之间无显著差异(P>0.05)。FT₃与BGP呈正相关。FT₄和FT₃与DPD呈正相关。股骨颈和大转子部位的BMD与FT₄呈负相关。
短期生理剂量左甲状腺素替代治疗可使甲状腺功能减退症患者的骨转换增加,并导致不同程度的骨量丢失。